Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Bulevirtide plus pegylated interferon shows promise for hard-to-treat coinfection.
Jeffrey V. Lazarus files a dispatch from Amsterdam, where the International Liver Congress is underway.
Those taking AbbVieâ€™s hepatitis C combo therapy virus who reduced their dose of ribavirin because of side effects, saw no reduction in...
Sofosbuvir and ribavirin cured participants with genotype 2 or 3 of hepatitis C virus at rates in the mid-70 percent range in two new Phase II...
AbbVie?s five-drug hepatitis C virus (HCV) combination therapy demonstrated cure rates in the mid-90 percent range when taken for as little as...
Hepatitis C therapy including daclatasvir, asunaprevir and BMS-791325 achieved a cure in up to 94 percent of treatment-naive people with genot...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.